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Objective. Most snakebite deaths occur prior to hospital arrival; yet inexpensive, effective, and easy to administer out-of-hospital
treatments do not exist. Acetylcholinesterase inhibitors can be therapeutic in neurotoxic envenomations when administered
intravenously, but nasally delivered drugs could facilitate prehospital therapy for these patients. We tested the feasibility of this
idea in experimentally envenomed mice. Methods. Mice received intraperitoneal injections of Naja naja venom 2.5 to 10 times
the estimated LD50 and then received 5𝜇L neostigmine (0.5mg/mL) or 5 𝜇L normal saline by nasal administration. Animals were
observed up to 12 hours and survivors were euthanized. Results. 100% of control mice died. Untreatedmice injected with 2.5× LD50
Naja naja died at average 193minutes after injection, while 10 of 15 (67%) of treatedmice survived andwere behaviorally normal by 6
hours (𝑃 < 0.02). In the 5× LD50 group, survival was prolonged from 45minutes to 196 minutes (𝑃 = 0.01) and for 10× LD50mice,
survival increased from 30 to 175 minutes (𝑃 < 0.02).Conclusion.This pilot suggests that intranasal drugs can improve survival and
is the first direct demonstration that such an approach is plausible, suggesting means by which treatment could be initiated before
reaching the hospital. Further investigation of this approach to neurotoxic and other types of envenomation is warranted.
1. Introduction
Bites from venomous snakes kill more people in the devel-
oping world than some of the world’s better recognized
and better studied neglected tropical diseases [1]. Recent
estimates suggest that worldwide there are more than 5
million snakebites occurring each year. Though not all bites
are by venomous snakes or result in poisoning, up to 2million
of these bites result in the injection of venom, with hundreds
of thousands of significant injuries and as many as 94,000
to 125,000 deaths occurring primarily in India, Southeast
Asia, and sub-Saharan Africa [2, 3]. The vast majority of
snakebites occur in impoverished, rural populations with
limited access tomedical treatment.Mortality from snakebite
is unequivocally linked to socioeconomic markers of poverty
and even a successful hospital treatment can cause economic
ruin. A recent study from the Indian state Tamil Nadu
analyzed how patients hospitalized for snakebite paid for
their expenses: 40% took loans, 20% sold stored crops, 15%
sold valuables 10% sold cattle, and many reported removing
their children from school—all while incurring up to 12 years
income worth of debt [2]. It is estimated that around 10,000
people die from snakebite each year in Tamil Nadu, alone
[2], more than twice the total number of deaths claimed by
landmines each year, worldwide [4, 5].
Neostigmine is an acetylcholinesterase inhibitor
(AChEI) that is administered intravenously and is currently
recommended by the WHO for the treatment of neurotoxic
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snakebite. Acetylcholinesterase inhibiting drugs such as
neostigmine and edrophonium are thought to reduce
the neuromuscular block from neurotoxic snakebite by
increasing the amount of acetylcholine at the neuromuscular
junction as it does in the treatment of myasthenia gravis
or the reversal of nondepolarizing neuromuscular blocking
agents [6–9]. Atropine or glycopyrrolate, in intravenous
(IV) form, are usually coadministered with AChEIs to blunt
the undesirable muscarinic effects of AChEIs. However,
coadministration is not necessary in some clinical studies, for
example, in myasthenia gravis patients receiving intranasal
(IN) administration for up to one year [10, 11]. Interestingly,
IN neostigmine has been used to treat myasthenia gravis
in several studies [10–13] and we recently showed in a
human study that it could reverse mivacurium-induced
neuromuscular blockade by this route [14].
The present study tested the hypothesis that neostigmine,
given IN, would be an effective initial treatment of Naja naja
envenomedmice.The early use of AChEIs leads to a consider-
able increase in the LD50 in mice and rats having undergone
experimental envenomation [15, 16]. Our study is distin-
guished from those by the replacement of parenteral neostig-
mine with topically applied IN neostigmine.The rationale for
this study is that since neurotoxic snakebites often occur far
from hospitals, by eliminating the need for injection (e.g., of
parenteral neostigmine or intravenous antivenin), we may be
able to shorten time to treatment and save lives.
2. Materials and Methods
2.1. Institutional. The study was approved by the animal
research committee of a contract research laboratory in
Hyderabad, India, an IACUC-certified laboratory and per-
formed by a trained technician, a full-time DVM and one of
us (MRL) who performed experiments at the facility.
2.2. Materials and Animals. Unfractionated N. naja venom
was purchased from Sigma-Aldrich (St. Louis, MO, USA);
neostigmine and atropine were purchased from Besse Medi-
cal (Ann Arbor, MI, USA). Venom and drugs were reconsti-
tuted in sterile water. Mice had access to water and food at
all times. Polyvalent antivenom (Vins Bioproducts, Andhra
Pradesh, India) was available at all times in the event of
accidental envenoming of staff.
2.3. Methods. A small pilot study was carried out to assess
the potency of the reconstituted lyophilized N. naja venom
to test if it was comparable to published reports of other
commercially available unfractionated, frozen, or lyophilized
N. naja venom at 0.3mg/kg [15, 17–19].
Mice were pseudorandomized in batches of 5 with tails
marked 1 to 5 stripes by Sharpie felt tip pen to receive
intraperitoneal (IP) injections of N. naja venom (2.5× LD50,
𝑁 = 20; 5× LD50,𝑁 = 10 and 10× LD50,𝑁 = 10) concomi-
tantly with atropine, which blunts the muscarinic effects of
neostigmine and has previously been shown to have no effect
on LD50 when experimentally injected with snake venom
[16].The IP agents (venomand atropine)were adjusted for the
weight of each individual mouse by the facility veterinarian
and injected by a single technician who was not aware of
the hypothesis and who also recorded the survival times.
Animals received either 5𝜇L of 0.5mg/mL neostigmine or
5 𝜇L of saline by IN administration by MRL. Animals in the
2.5× LD50 group received treatment or control 10 minutes
after venom injection. In the 5× LD50 and 10× LD50 groups,
animals received IN neostigmine 1-2 minutes after venom
injection. Preliminary studies the mice were already severely
disabled by 10 minutes after experimental envenomation
with the higher doses of venom and neostigmine did not
appear to help. Animals were observed continuously for
up to 12 hours and assessed for signs of toxicity including
respiratory distress, loss of spontaneous locomotor activity
with the only endpoints being time to death or recovery.
Deadmice were removed immediately and tail-band number
was recorded on a data sheet reflecting the mouse’s lot and
individual band number as well as weight. Surviving animals
were euthanized after 12 hours by the same technician who
performed the experimental envenomation procedure. The
technician, however, was blinded to knowing whichmice had
been treated with IN neostigmine or saline control.
2.4. Data Analysis and Presentation. Data were analyzed
using GraphPad Prism (La Jolla, CA) and the 𝑃 values
presented in the figures were as calculated by nonparametric
Mann-Whitney test. Envenomed mice were further charac-
terized using a survival analysis that included censoring to
account for the study being terminated at 12 hours (720
minutes) after dosing. To plot survival time on a single 𝑦-
axis, the survival time data was normalized within each
envenomation dose to the mean survival time of each control
group and then multiplied by 100.
3. Results
Because snakebites in the community can result in a highly
variable amount of venom being delivered to the patient,
we sought to determine whether IN neostigmine could be
effective in improving survival at several dosages of venom
in our mouse model. There were no statistically significant
differences in animal weight between any of the groups.
Figures 1(a)–1(c) show the effects of neostigmine in mice
envenomed withNaja naja venom at various concentrations:
2.5× LD50 (a), 5× LD50 (b), and 10× LD50 (c). As described
above, the rationale for using IN neostigmine is to improve
survival time from themoment of the snakebite.These results
support our idea that early IN AChEI therapy could improve
survival even after a potentially severe neurotoxic enveno-
mation. Higher venom dosages resulted in earlier deaths, as
expected, but for all dosages of venom, neostigmine provided
a substantial and persistent window of increased survival.
Table 1 summarizes the data from all groups. At 2.5× LD50,
envenomedmice died at an average of 193 minutes compared
to 553 minutes (𝑃 < 0.02) for the treatment group (10/15
were euthanized after the arbitrary cutoff of 6 hours, but
were behaving completely normally). At the 5× LD50 venom
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Figure 1: Kaplan-Meier plot of survival times in mice given 2.5 (a),
5 (b), or 10 (c) times the LD50 of N. naja venom and either a single
dose of IN neostigmine (treatment groups, blue lines) or IN saline
(control groups, red lines). 𝑁 = 5 animals for each group, except
𝑁 = 15 for the 2.5× LD50 treatment group.Therewere no significant
differences in the mean weight of animals across groups.
dosage, survival was prolonged from amean of 45 minutes in
the control group to 196 minutes in the treatment group (𝑃 =
0.01). Likewise, at the 10×LD50 venomdosage,mean survival
was prolonged from 30 to 175 minutes (𝑃 < 0.02). Findings
reached statistical significance even after reanalysis excluding
surviving outliers in the 5× LD50 and 10× LD50 groups.
4. Limitations
Most bites in humans are on the extremities, but we chose
the IP route for consistency and to replicate elements of
previously published mouse studies [15–17]. Due to limita-
tions of funding, we only tried one type of experimental
envenomation using a curare-like snake neurotoxin; it is
likely that the effects of IN AChEIs will vary across different
venom types. Venoms contain a multitude of toxic peptides
and proteins and published LD50 ranges vary widely between
cobra species, subspecies and route of delivery (e.g., subcu-
taneous, intravenous, or IP) [15, 17–20]. Mice and humans
differ greatly in their sensitivity to the same drugs [21, 22],
and only one set of neostigmine to atropine concentrations
was used. Thus, as with all transitions from preclinical to
clinical usage, dosages will need to be optimized for human
use. Fortunately, the development of IN neostigmine for the
treatment of myasthenia gravis [10–13, 23, 24] provides a
substantial head start for this transition. Only a single dose
of IN neostigmine was administered, so it is not clear if
mice would have survived longer with multiple treatments
and no other AChEIs were tested. The concentration of
neostigmine was significantly lower than that has been used
in human studies, though total dose was comparable and the
drugs were not aerosolized but dropped on the nares [10–
14]. In the present study, atropine was coadministered with
IN neostigmine through IP route. In previous mouse studies
atropine has been administered IP without changing the
LD50 of cobra venom [15]. We anticipate that an anticholin-
ergic agent such as atropine (which can be administered IN)
would potentially be administered with neostigmine to blunt
untoward muscarinic effects of an AchEI should these effects
be present with IN AChEI formulations in a human study
[25]. Interestingly, in the year-long study by Sghirlanzoni
and colleagues, patients self-administering IN neostigmine
did not report any complications from IN neostigmine [11].
Broggini and colleagues tested the bioavailability of high
dose IN neostigmine compared to IV administration in
healthy human adults without coadministration of atropine
and did not note any serious adverse events [23]. The IP-
absorption kinetics of atropine are more reliable and proven
than the IN absorption kinetics of atropine. Thus, if we
had coadministered atropine IN instead of IP, we would
be faced with the confoundedness that perhaps differential
survival depended on intersubject differences in atropine-
absorption kinetics. This confoundedness would be impos-
sible to disambiguate from our central hypothesis in such a
small study. By contrast, if survival depended on differential
IN absorption kinetics (of neostigmine), that simply serves
to further support the central hypothesis that neostigmine
is the critical variable, especially in light of Gieu’s results
showing that IP atropine did not materially alter survival
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Table 1: Survival times for all venom dosages compared with and without IN neostigmine treatment. 𝑃 values shown were as calculated by
nonparametric Mann-Whitney test.
Treatment Mean survival time in minutes (range) 𝑃 value Number of mice per group
2.5× LD50 venom 193 (67–332)
<0.02 5
2.5× LD50 + neostigmine 553 (144–720) 15
5× LD50 45 (40–48) =0.01 5
5× LD50 + neostigmine 196 (50–720) 5
10× LD50 30 (25–35)
<0.02 510× LD50 + neostigmine 175 (35–720) 5
from experimental IP cobra envenomation [15]. We did not
do necropsy on the mice. Similarly, we did not attempt
any skin hemorrhagic or myonecrosis activity assays, though
no unusual bleeding was noted. Mice were only observed
for neurological manifestations of envenomation such as
convulsion, hind limb paralysis, and respiratory distress after
injection of reconstituted venom [17].
5. Discussion
Muscle-contraction-dependent respiration is a necessary
condition for life amongst all mammals and virtually all
vertebrates.The present finding builds on our earlier demon-
stration that IN neostigmine could reverse paralysis in an
awake, experimentally paralyzed human subject [14]. To our
knowledge, this is the first demonstration that a topically
applied drug could reverse venom-induced neurotoxicity.
We previously showed that nasal neostigmine could reverse
mivacurium-induced paralysis in an awake human [14].
Together, these data provide proof-of-principle that venom-
induced toxicity should be treatable in the out-of-hospital
setting and provide early, life-saving interventions at low cost.
There is evidence for neostigmine-resistant envenomings
[26] in humans. Anil and colleagues showed that the mean
time interval between bite and arrival to hospital was 4.5 h
by which point the venom would have been entrenched at
presynaptic axons [26]. Rapid death from krait bite most
often comes as a result of the alpha-toxin and diaphragmatic
paralysis and airway obstruction could be delayed by early
AChEI therapy, but to our knowledge this idea has never been
tested. Inmouse studies, Guieu showed that among the drugs
they tested only AChEIs consistently resulted in increases in
Naja venom LD50s while atropine had no effect on the LD50
[15]. Similarly, Flachsenberger [16] showed that at otherwise
lethal doses, all animals survived as a result of early AChEI
treatment following IP administration of adder (Acanthophis
antarcticus) venom. Flaschenberger further found that the
expected survival time of animals subjected to even higher
experimental venom doses was significantly extended. These
animal [15, 16] and human morbidity and mortality studies
suggest that if AChEIs can be administered during the initial,
critical stage after envenomation there could be a survival
benefit to human victims [16, 27–32].
Surprisingly, both the efficacy and optimal uses of
antivenom and AChEI therapies for neurotoxic snakebite
remain unproven even after decades of widespread use [2,
14, 33–38]. It has been argued that the development of more
diverse and regionally specific antivenoms is the most cost
effective means of combatting morbidity and mortality from
snakebite in the developing world [39–41]. We argue that
investment in repurposed, low-molecular-weight pharma-
ceuticals would be more cost effective in the long term
because of their ease of use, heat stability, and safety profiles.
IN administration of neostigmine has the potential to provide
snakebite victims with significantly increased access to an
effective treatment for neurotoxic snakebite while suggesting
a strategy for the development of topically administered
antidotes to hemotoxic, cardiotoxic, and other complex
envenomation in the future. This type of innovation would
save lives while significantly lowering the economic burden
on individuals, families, communities, and governments. To
date, no prospective human study has been done to analyze
the effect of immediate AChEI administration in the setting
of neurotoxic snakebite. The primary aim of this pilot study
was to test if early IN administration of AChEIs and in
principal any venom-inhibiting agent is plausible.The results
of this study suggest that this is the case and that significant
further study of this and other strategies is warranted.
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